These results suggested that GEM combined with MG-132, Dasatinib, Shikonin, Midostaurin, MS-275, and Z-LLNle-CHO might treat CRC through the action of CALB2 and GPX3. The gene discussed is CALB2; the disease is colorectal carcinoma.